April 24, 2014


NASERUDDIN HÖTI, Ph.D.

Instructor
Department of Urology, Johns Hopkins University School of Medicine


Email:nhoti1@jhmi.edu

RESEARCH AND PROFESSIONAL EXPERIENCE
Prostate cancer affects one in six men and is the second leading cause of cancer death among men in the United States. Conventional therapies may lead to resistant cancer which is merely managed and not cured. Gene therapy using Adenoviral vectors have shown promise as a treatment strategy that can target both localized and metastatic prostate cancer. The main mission of our group is to translate advances in imaging, oncology, and virology into innovative gene therapy based cancer therapeutics. Using molecular techniques to specifically re-target the viral vector to prostate cancer cells as well as shortening the life cycle of these viruses in order to invade and kill the tumor before they are cleared from the body.

 

© Copyright 2014 | All Rights Reserved | Disclaimer
Email: webmaster@urology.jhu.edu | 600 North Wolfe Street, Baltimore, Maryland 21287